نتائج البحث - "Rene K Olesen"

1

دورية أكاديمية

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

المصدر: Health Technology Assessment, Vol 23, Iss 64 (2019)

مصطلحات موضوعية: oxaliplatin, capecitabine, disease-free survival, chemotherapy, adjuvant, quality-adjusted life-years, colorectal neoplasms, fluorouracil, randomised controlled trial, Medical technology, R855-855.5

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1366-5278Test; https://doaj.org/toc/2046-4924Test

الوصول الحر: https://doaj.org/article/4215111445164519a465163178fd46e0Test

View record in DOAJ

النص الكامل

2

Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic colorectal cancer treated with regorafenib

المؤلفون: Dennis Tønner Nielsen, Iben R Andersen, Anders Boysen, Lars Henrik Jensen, Finn Rasmussen, Rene K Olesen, Frank Viborg Mortensen

المصدر: Andersen, I R, Olesen, R, Boysen, A K, Jensen, L H, Mortensen, F V, Nielsen, D T & Rasmussen, F 2019, ' Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic colorectal cancer treated with regorafenib ', Acta Radiologica, vol. 60, no. 7, pp. 836-845 . https://doi.org/10.1177/0284185118806652Test

مصطلحات موضوعية: Male, Lung Neoplasms, dynamic contrast-enhanced computed tomography, Pyridines, Colorectal cancer, Angiogenesis, Contrast Media, Lung Neoplasms/diagnostic imaging, 030218 nuclear medicine & medical imaging, chemistry.chemical_compound, 0302 clinical medicine, Liver Neoplasms/diagnostic imaging, CT quantitative, Radiographic Image Enhancement/methods, Abdominal Neoplasms/diagnostic imaging, skin and connective tissue diseases, Four-Dimensional Computed Tomography/methods, Pyridines/therapeutic use, Radiological and Ultrasound Technology, metastatic colorectal cancer, Liver Neoplasms, Dynamic Contrast Enhanced Computed Tomography, General Medicine, Middle Aged, Radiographic Image Enhancement, Treatment Outcome, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Cohort, Biomarker (medicine), Female, Radiology, Colorectal Neoplasms, Perfusion, patient outcome, medicine.medical_specialty, 03 medical and health sciences, Triiodobenzoic Acids, Regorafenib, medicine, Humans, Radiology, Nuclear Medicine and imaging, Four-Dimensional Computed Tomography, Phenylurea Compounds/therapeutic use, Aged, Colorectal Neoplasms/pathology, business.industry, Phenylurea Compounds, angiogenesis inhibitors, medicine.disease, chemistry, Abdominal Neoplasms, business, Biomarkers

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::085dde37d6a9e67d28dec1e603503b0eTest
https://doi.org/10.1177/0284185118806652Test

3

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer

المؤلفون: Lars Henrik Jensen, Lone Petersen, Jan Lindebjerg, Torben Hansen, Anders Kindberg Boysen, Caroline Brenner Thomsen, Rikke Fredslund Andersen, Rene K Olesen, Lise Nottelmann, Anders Jakobsen, Birgitte Mayland Havelund

المصدر: Jensen, L H, Olesen, R, Petersen, L N, Boysen, A K, Andersen, R F, Lindebjerg, J, Nottelmann, L, Thomsen, C E B, Havelund, B M, Jakobsen, A & Hansen, T F 2019, ' NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer ', Cancers, vol. 11, no. 11, 1649 . https://doi.org/10.3390/cancers11111649Test
Cancers, Vol 11, Iss 11, p 1649 (2019)
Cancers
Volume 11
Issue 11

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d11a84bc51e9aca97d7ceb228909ae86Test
https://findresearcher.sdu.dk:8443/ws/files/156479905/NPY_Gene_Methylation_as_a_Universal.pdfTest

4

Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability

المؤلفون: Rene K Olesen, Morten Ladekarl, Henning Grønbæk, Anne Helene Køstner, Ulrik Lassen, Morten Sorensen

المصدر: Køstner, A H, Sørensen, M, Olesen, R K, Grønbæk, H, Lassen, U & Ladekarl, M 2013, ' Sorafenib in advanced hepatocellular carcinoma : a nationwide retrospective study of efficacy and tolerability ', Scientific World Journal, vol. 2013, pp. 931972 . https://doi.org/10.1155/2013/931972Test
The Scientific World Journal, Vol 2013 (2013)
The Scientific World Journal

مصطلحات موضوعية: Male, Niacinamide, Sorafenib, Oncology, medicine.medical_specialty, Carcinoma, Hepatocellular, Article Subject, lcsh:Medicine, Antineoplastic Agents, lcsh:Technology, General Biochemistry, Genetics and Molecular Biology, Internal medicine, medicine, Carcinoma, Humans, lcsh:Science, Aged, Retrospective Studies, General Environmental Science, Performance status, lcsh:T, business.industry, Phenylurea Compounds, Liver Neoplasms, lcsh:R, Retrospective cohort study, General Medicine, Middle Aged, Prognosis, medicine.disease, digestive system diseases, Surgery, Clinical trial, Treatment Outcome, Liver, Tolerability, Hepatocellular carcinoma, Hypertension, Clinical Study, Female, lcsh:Q, alpha-Fetoproteins, Liver function, business, Biomarkers, medicine.drug

وصف الملف: text/xhtml

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0250be874bf91b3306220dc13b8ba60cTest
https://doi.org/10.1155/2013/931972Test

5

Tumor specific methylation of NPY compared to RAS mutation in plasma DNA in the monitoring of colorectal cancer patients treated with last-line regorafenib

المؤلفون: Birgitte Mayland Havelund, Torben Hansen, Anders Jakobsen, Lise Nottelmann, Lars Henrik Jensen, Rikke Fredslund Andersen, Anders Kindberg Boysen, Caroline Brenner Thomsen, Rene K Olesen

المصدر: Jensen, L H, Brenner Thomsen, C E, Olesen, R K, Boysen, A K, Hansen, T F, Nottelmann, L, Havelund, B M, Fredslund Andersen, R & Jakobsen, A 2018, ' Tumor specific methylation of NPY compared to RAS mutation in plasma DNA in the monitoring of colorectal cancer patients treated with last-line regorafenib ', Journal of Clinical Oncology, vol. 36, no. 15 Supplement, e15541 . https://doi.org/10.1200/jco.2018.36.15_suppl.e15541Test

مصطلحات موضوعية: Cancer Research, business.industry, Colorectal cancer, Plasma dna, Tumor specific, Methylation, medicine.disease, chemistry.chemical_compound, Oncology, chemistry, Refractory, Regorafenib, RAS Mutation, Cancer research, Medicine, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d492237b425dff46d8db61c521777cTest
https://doi.org/10.1200/jco.2018.36.15_suppl.e15541Test

6

Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

المؤلفون: Peter Carmeliet, Rene K Olesen, Helle Pappot, Ian Buysschaert, Morten Sorensen, Gunilla Høyer-Hansen, Kristoffer Staal Rohrberg, Ulrik Lassen, Morten Ladekarl, Birgit Guldhammer Skov, Ib Jarle Christensen, Per Pfeiffer

المصدر: Rohrberg, K S, Olesen, R K, Pfeiffer, P, Ladekarl, M, Pappot, H, Christensen, I J, Høyer-Hansen, G, Sørensen, M, Skov, B G, Buysschaert, I, Carmeliet, P & Lassen, U 2012, ' Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers ', Acta Oncologica, vol. 51, no. 2, pp. 234-242 . https://doi.org/10.3109/0284186X.2011.619568Test
Rohrberg, K S, Olesen, R K, Pfeiffer, P, Ladekarl, M, Pappot, H, Christensen, I J, Høyer-Hansen, G, Sørensen, M, Skov, B G, Buysschaert, I, Carmeliet, P & Lassen, U 2012, ' Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers ', Acta Oncologica. Supplement, vol. 51, no. 2, pp. 234-42 . https://doi.org/10.3109/0284186X.2011.619568Test

مصطلحات موضوعية: Oncology, Adult, Male, medicine.medical_specialty, Bevacizumab, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Disease-Free Survival, chemistry.chemical_compound, Erlotinib Hydrochloride, Internal medicine, Clinical endpoint, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Epidermal growth factor receptor, Progression-free survival, Prospective Studies, Survival analysis, Aged, Gastrointestinal Neoplasms, biology, Dose-Response Relationship, Drug, business.industry, Carcinoma, Hematology, General Medicine, Middle Aged, Survival Analysis, Surgery, Vascular endothelial growth factor, ErbB Receptors, Treatment Outcome, chemistry, Drug Resistance, Neoplasm, biology.protein, Quinazolines, Biomarker (medicine), Drug Therapy, Combination, Female, Erlotinib, Receptor, Epidermal Growth Factor, business, medicine.drug, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b33fb99d6c615fbb39c67dd38b78e917Test
https://portal.findresearcher.sdu.dk/da/publications/5307d1be-e559-4bae-8042-9a86a49b1193Test

7

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

المؤلفون: Morten Sorensen, Per Pfeiffer, Maj Westman, Ulrik Lassen, Birgit Guldhammer Skov, Ib Jarle Christensen, Kristoffer Staal Rohrberg, Helle Pappot, Morten Ladekarl, Rene K Olesen

المصدر: Rohrberg, K S, Pappot, H, Lassen, U, Westman, M, Olesen, R K, Pfeiffer, P, Ladekarl, M, Sørensen, M, Christensen, I J & Skov, B G 2011, ' Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab ', Cancer Biology & Therapy, vol. 11, no. 8, pp. 732-9 .
University of Southern Denmark
Aalborg University

مصطلحات موضوعية: Oncology, Adult, Male, Vascular Endothelial Growth Factor A, Cancer Research, medicine.medical_specialty, Combination therapy, Bevacizumab, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Proto-Oncogene Proteins p21(ras), Erlotinib Hydrochloride, Internal medicine, Proto-Oncogene Proteins, medicine, Biomarkers, Tumor, Humans, Epidermal growth factor receptor, Progression-free survival, Survival analysis, Aged, Gastrointestinal Neoplasms, Pharmacology, biology, Cancer, Antibodies, Monoclonal, Middle Aged, medicine.disease, Survival Analysis, Vascular Endothelial Growth Factor Receptor-2, ErbB Receptors, Treatment Outcome, Tumor Markers, Biological, Mutation, Cancer research, biology.protein, Quinazolines, ras Proteins, Molecular Medicine, Biomarker (medicine), Female, Erlotinib, Receptor, Epidermal Growth Factor, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b7450dc6bcab6c1eeb6efde6f180520Test
https://portal.findresearcher.sdu.dk/da/publications/10c42264-083e-4d41-9b2d-2d15f45e2fc2Test

8

PP63 Predictive markers in patients with upper gastrointestinal (GI) cancers treated with erlotinib and bevacizumab in a multicenter phase II trial

المؤلفون: Peter Carmeliet, Helle Pappot, Kristoffer Staal Rohrberg, Rene K Olesen, B. Guldhammer Skov, Per Pfeiffer, Ian Buysschaert, Morten Ladekarl, Ulrik Lassen, Ib Jarle Christensen

المصدر: European Journal of Cancer Supplements. 7:28

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Bevacizumab, business.industry, Internal medicine, medicine, Upper gastrointestinal, In patient, Erlotinib, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::863b849c5ef502a1d23e77995037d2cbTest
https://doi.org/10.1016/s1359-6349Test(09)72203-7

تنقيح النتائج